Australian Deprescribing Network
Promoting research, awareness, practice and policy on deprescribing to improve the safe and appropriate use of medicines for all Australians.
Innovative service models to support deprescribing in hospital
Sedative and anticholinergic drugs are commonly associated with harm in older adults. The Drug Burden Index (DBI) developed by Professor Sarah Hilmer, is a validated clinical risk assessment tool which measures exposure to anticholinergics and sedatives. A bundle of resources, including the DBI in the electronic Medical Records (eMR) have been implemented in Northern Sydney Local Health District (NSLHD) and Central Coast Local Health District (CCLHD) hospitals in NSW, to help clinicians identify and prioritise high-risk older patients for medication review and facilitate deprescribing of DBI-contributing drugs where appropriate.
Click here to read more!
Research
Researchers across Australia and internationally are working on projects to inform deprescribing in practice.
Events
Click through to find out about our upcoming events.
Contact Us
Click here for detail on how to contact us, including media contacts. You can also subscribe to our newsletter.
Latest research
GP preferences for discussing statin deprescribing: a discrete choice experiment
Date: 2021
Thompson, Wade, et al. “GP preferences for discussing statin deprescribing: a discrete choice experiment.” Family Practice (2021).
Leveraging implementation science to increase the translation of deprescribing evidence into practice
Date: 2021
Citation: Ailabouni, Nagham J., et al. “Leveraging implementation science to increase the translation of deprescribing evidence into practice.” Research in Social and Administrative Pharmacy (2021).
Appropriate deprescribing in older people: a challenging necessity Commentary to accompany themed collection on deprescribing
Date: 2021
Citation: van der Velde, Nathalie, and Jatinder S. Minhas. “Appropriate deprescribing in older people: a challenging necessity Commentary to accompany themed collection on deprescribing.” Age and Ageing (2021).
The ADeN 2024 annual meeting is not too far away!
⏰ We are extending our abstract deadline by another week! Please submit your abstract by the 17th of October: 😊
Day 2 kicks of @ICOD2024 with @AiliLangford from #SydneyPharmacySchool discussing #deprescribing recommendations within guidelines!
About the Australian Deprescribing Network
Who is ADeN and why do we exist?
The Australian Deprescribing Network (ADeN) comprises of clinicians, academic researchers, policy makers, students and consumers working together to develop the evidence-base, clinical guidance and knowledge translation to facilitate deprescribing of medicines that are no longer providing benefit or are causing harm.
ADeN aims to promote research, awareness, practice and policy for the safe and appropriate use of medicines for all Australians.
This website aims to share and exchange information about deprescribing approaches and deprescribing research with the public, health care providers and researchers.
What is Deprescribing?
Deprescribing is the planned and supervised process of dose reduction or stopping of medication that might be causing harm, or no longer be of benefit.
Deprescribing is part of good prescribing – backing off when doses are too high, or stopping medications that are no longer needed.
To become an ADeN member, sign up to our email list and hear about upcoming opportunities, news, events and more!
Contact us
For general enquiries fill out our online contact form. Copyright 2021. Read our disclaimer.